We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Women with Gestational Diabetes Need Retesting After Pregnancy

By LabMedica International staff writers
Posted on 12 May 2010
Women who have had gestational diabetes should be retested for diabetes 6 to 12 weeks after the baby is born, and at least every three years after that. More...
Follow-up screening usually consists of a simple blood test.

Generally, steps are taken to manage gestational diabetes during pregnancy for the health of both mother and child. However, many women do not realize that if they have had gestational diabetes they are at increased risk for developing diabetes in the future, and their child is also at increased risk for obesity and type 2 diabetes.

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; Bethesda MD, USA) and the Office of Research on Women's Health (ORWH; Bethesda, MD, USA) are together promoting awareness of risks attached for mothers and children after pregnancies where there had been gestational diabetes. A special effort was made from May 9-15, 2010, which included Mother's Day in many parts of the world, and [US] National Women's Health Week.

"Many women think that if the follow-up test after the baby is born shows no signs of diabetes, they are in the clear, but that is not the case," said Vivian Pinn, M.D., director of the ORWH. "What many of these moms do not know is that they have a 40 % to 60 % chance of developing diabetes as early as five to 10 years after their baby is born. These women need to know this information and they need to take steps to lower their risk for developing diabetes."

Related Links:
U.S. National Institute of Diabetes and Digestive and Kidney Diseases
Office of Research on Women's Health



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.